Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study Meeting Abstract
| Authors: | Oh, D. Y.; Janjigian, Y. Y.; Al-Batran, S. E.; Wainberg, Z. A.; van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L. S.; Omori, T.; Moehler, M.; Garrido, M.; Cunha Sousa Oliveira, S.; Liberman, M.; Castro Oliden, V.; Bilici, M.; Kurland, J.; Xynos, I.; Mann, H.; Tabernero, J. |
| Abstract Title: | Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study |
| Meeting Title: | ESMO Asia Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2023 Dec 1-3 |
| Meeting Location: | Singapore |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-11-01 |
| Start Page: | S1520 |
| End Page: | S1521 |
| Language: | English |
| ACCESSION: | WOS:001122475400133 |
| DOI: | 10.1016/j.annonc.2023.10.265 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 129O -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
